Orum Therapeutics, Inc. 475830

KRX · South Korea · Health Technology

KRW 21,150.00-2,200.00 (-9.42%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Company news

Yahoo FinanceAug 23, 2026

Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate

Company to host a conference call to discuss the ORM-1153 IND clearance and provide a high-level overview of the Phase 1 clinical studyBOSTON and DAEJEON, South Korea, Aug. 22, 2026 (GLOBE NEWSWIRE) -- Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ORM-1153, a CD12

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.